Study Notes on Genetic Polymorphisms and Genome-Wide Association Studies in Cancer

Multiple cancers as complex polygenic disorders.
Importance of genetic variation in cancer risk.
Focus on BRCA1 and BRCA2 in early-onset familial breast cancer.
Introduction to genome-wide association studies (GWAS) related to complex traits.
Discussion on common genetic variants and their contribution to heritable risk of common cancers with selected examples.
New insights into cancer biology and mechanisms.
Introduction of polygenic risk scores.
Overview of drug development implications.
Challenges and opportunities ahead.

Understanding Heritable Components: Examine how genetic predispositions contribute to diseases.
Pathogenic Mechanism Elucidation: Identify underlying mechanisms causing diseases.
Gene-Environment Interactions: Study interplay between genetics and environmental factors influencing disease.
Therapeutic Innovation: Develop new therapeutic strategies based on genetic findings.
Early Diagnosis and Prevention: Design methods for early detection and intervention.
Pharmacogenetics: Customize drug therapies to target individuals most likely to respond positively.

Aggregate in Families: Increase in cancer incidence among relatives.
- Prostate Cancer: 2.5 times higher risk for those with one affected first-degree relative; 5 times higher for two or more affected relatives.
- Colorectal Cancer: 1.7 times risk increase for those with affected relatives; 2.75 times for those with two or more.
- Breast Cancer: Women with affected first-degree relatives have an 1.80 fold increased risk compared to those with no affected relatives.

Heritability measures how much variation in a trait is attributable to genetic factors.
- Values closer to 100 suggest high heritability within a population.
- Prospective study of twin registers: 80,309 monozygotic twins and 123,382 same-sex dizygotic twins (total N = 203,691) in Nordic countries.

Simple Traits: Characteristics influenced by single genes (e.g., Cystic Fibrosis).
Complex (Polygenic) Traits: Characteristics influenced by multiple genes and environmental factors (e.g., Cancer).

Human genome is approximately 2.9 billion nucleotides long with around 20,000 genes and over 80 million SNPs.
SNPs occur approximately once every 500-1000 nucleotides, constituting the majority of genetic variation.
Other forms of variation include deletions, insertions, and expansions of tandem repeats.

Effect Size: Quantification of the impact that genetic variants have on disease risk.
- High effect size (50.0): Examples include BRCA1, BRCA2, TP53, MLH1.
- Intermediate effect size (3.0) includes rare alleles causing Mendelian disease.
- Low effect size (1.5 to 1.0) represents modest effects that are harder to identify genetically.
- Very rare variants with low frequency can still influence disease risk (effect sizes below 0.001).

Positional Cloning and Linkage Analysis are traditional methods for identifying genetic markers linked to disease.
In GWAS, a case-control design is employed comparing genotypes from disease patients and healthy controls using arrays that test over 500,000 SNPs.
Researchers apply stringent corrections for multiple testing to identify disease-specific SNPs.

About 10% of breast cancer cases occur in women with a family history of breast cancer.
Inherited mutations (BRCA1, BRCA2, among others) found in 20-25% of families.
60% of women with harmful BRCA mutations develop breast cancer; general population risk is ~13%.
Harmful BRCA mutations are also associated with increased risk for pancreatic and prostate cancers.

DNA Maintenance Regulators: They are crucial in maintaining genetic integrity during cell replication.
PARP Inhibitors exploit BRCA-deficiency by inducing cell death through failure to repair DNA damage.

Human Genome Project: Completed in 2003; it successfully sequenced all 3 billion nucleotides, identifying around 20,000 genes.
Subsequent initiatives like the HapMap Project and the ENCODE Project have expanded our understanding of genomic structures.

GWAS investigate associations across the entire genome focused on >500,000 SNPs.
Designed as case-control studies with large populations and strict control for stratification.
Platforms utilized include Affymetrix and Illumina technology.
A statistically significant association is defined as a p-value less than $5 imes 10^{-8}$ .

Genotyping methods analyze specific SNP sequences to detect polymorphisms.
Imputation combines genotype data with reference haplotypes to fill in missing genotype information.

GWAS Catalog: Curated database of human GWAS findings managed by NHGRI-EBI.
The relation of SNPs with specific cancers is documented allowing for search by traits, genes, and studies.

Melanoma Case Control Study: Meta-analysis of 36,760 cases and 375,188 controls identified 54 significant loci associated with melanoma risk.
- Analysis of independent SNPs across geographical and host factor variations.
- Pathways revealed include pigmentation and telomere maintenance significance in melanoma susceptibility.

Meta-analysis on mammographic density (MD) among women indicated 39 SNPs associated with breast cancer risk.
- Functional inference explored genes significantly associated with variants affecting mammographic density.

GWAS examining shared genetic risks across cancers found significant associations in multiple cancer types, elucidating cross-cancer genetic links.

Pleiotropy refers to the ability of a single gene to influence multiple traits or diseases, observed in analyses like the ones linking genetic variants to multiple cancer types.

Polygenic risk scores have been linked to cancer diagnostics and prognostics, emphasizing their potential for exploratory and clinical use.

Future challenges include uncovering additional genetic variants and their translation into practical therapies.
Efforts are directed toward leveraging large-scale whole-genome sequencing, examining gene-environment interactions, and investigating epigenetic influences.

Recommended articles discuss GWAS advancements and implications for cancer research, offering extensive insights into the evolving landscape of cancer genomics.

Engaging discussions on the implications of the presented findings and future potential research directions in the field of cancer genetics.